PL372661A1 - Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections - Google Patents

Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Info

Publication number
PL372661A1
PL372661A1 PL03372661A PL37266103A PL372661A1 PL 372661 A1 PL372661 A1 PL 372661A1 PL 03372661 A PL03372661 A PL 03372661A PL 37266103 A PL37266103 A PL 37266103A PL 372661 A1 PL372661 A1 PL 372661A1
Authority
PL
Poland
Prior art keywords
oxazolidinones
parenteral
intravenous
oral administration
diabetic foot
Prior art date
Application number
PL03372661A
Other languages
English (en)
Polish (pl)
Inventor
Carl Norden
Original Assignee
Pharmacia & Upjohn Company Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc. filed Critical Pharmacia & Upjohn Company Llc.
Publication of PL372661A1 publication Critical patent/PL372661A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL03372661A 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections PL372661A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
PL372661A1 true PL372661A1 (en) 2005-07-25

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372661A PL372661A1 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Country Status (16)

Country Link
US (1) US20030216330A1 (enExample)
EP (1) EP1490059A1 (enExample)
JP (1) JP2005527575A (enExample)
KR (1) KR20040095328A (enExample)
CN (1) CN1642543A (enExample)
AU (1) AU2003223334A1 (enExample)
BR (1) BR0308806A (enExample)
CA (1) CA2476545A1 (enExample)
IL (1) IL164195A0 (enExample)
MX (1) MXPA04009356A (enExample)
NO (1) NO20044672L (enExample)
NZ (1) NZ535648A (enExample)
PL (1) PL372661A1 (enExample)
RU (1) RU2354372C2 (enExample)
WO (1) WO2003084534A1 (enExample)
ZA (1) ZA200407734B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
AU2004267007C1 (en) 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
TW200612923A (en) * 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
EP1745784A1 (en) * 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
JP2008544979A (ja) 2005-06-29 2008-12-11 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌剤としてのホモモルホリンオキサゾリジノン
WO2009032470A2 (en) * 2007-08-22 2009-03-12 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant staphylococcus aureus
TW201036609A (en) * 2009-03-16 2010-10-16 Astrazeneca Ab Compound for the treatment of tuberculosis
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
CA2119556C (en) * 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
HUT74099A (en) * 1992-12-08 1996-11-28 Upjohn Co Tropone-substituted phenyloxazolidinone antibacterial agents and pharmaceutical compositions containing the same
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
PT792273E (pt) * 1994-11-15 2003-06-30 Upjohn Co Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
FI980452A7 (fi) * 1995-09-01 1998-02-27 Upjohn Co Fenyylioksatsolidinoneja, jotka ovat liittyneet C-C-sidoksella 4-8-jäs enisiin heterosyklisiin renkaisiin
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
US6239152B1 (en) * 1998-01-23 2001-05-29 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
ATE301474T1 (de) * 2000-06-30 2005-08-15 Pharmacia & Upjohn Co Llc Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten

Also Published As

Publication number Publication date
MXPA04009356A (es) 2005-01-25
IL164195A0 (en) 2005-12-18
US20030216330A1 (en) 2003-11-20
RU2354372C2 (ru) 2009-05-10
WO2003084534A1 (en) 2003-10-16
CA2476545A1 (en) 2003-10-16
EP1490059A1 (en) 2004-12-29
KR20040095328A (ko) 2004-11-12
CN1642543A (zh) 2005-07-20
BR0308806A (pt) 2005-01-04
AU2003223334A1 (en) 2003-10-20
ZA200407734B (en) 2005-06-24
JP2005527575A (ja) 2005-09-15
RU2004131830A (ru) 2005-04-10
NO20044672L (no) 2004-12-23
NZ535648A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
IL164195A0 (en) Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
TW200505881A (en) Tri(cyclo) substituted amide compounds
NO20053224D0 (no) Patient controlled drug administration device.
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
IL239913B (en) The use of delvavancin in a pharmaceutical carrier is accepted in the production of a drug for the treatment of bacterial infections
IN2015DN01132A (enExample)
EP1545483A4 (en) NON-NUCLEOSIDIC INHIBITORS OF INVERSE TRANSCRIPTASES
EP1477119A4 (en) METHOD OF DRUG DELIVERY
IL136512A0 (en) Intravenous infusion administration set
TW200806295A (en) Long term treatment of HIV infection
EP1783137A4 (en) GALACTOSIS DERIVATIVE, DRUG VECTOR AND THERAPEUTIC PREPARATION
NO20013958L (no) Legemiddel for behandling av höyt blodtrykk
AU2003252182A8 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
IL158794A0 (en) The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes
IT1308678B1 (it) Siringa per infusione di farmaci.
GEP201606538B (en) Preoperative treatment of post operative pain
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
AU2003217677A8 (en) Probe-activated medicament injector device
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
RU2004105675A (ru) Способ комплексного лечения язв роговицы
UA90843C2 (ru) Соединения три(цикло)-замещенных амидов
EP1526838B8 (de) Intravenös applizierbare, pharmazeutische darreichungsform
PL362702A1 (en) Pharmaceutical composition for the treatment of diabetes comprising a 5-phenoxyalkal-2,4-thiazolidinedione derivative and a compound that stimulates insulin secretion
EG23366A (en) Oral film containing chlorhexidine hydrochloride and benzydamine hydrochloride for treatment of gingivitis, peridontitis and oral infections.
ITCT20020009V0 (it) Deflussore autobloccante per infusione endovenosa anti-embolia.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)